111.   The company argues that the Justice Department has been gathering information for its case for more than a year and that Microsoft deserves its own chance.

112.   The company argues that the three generic companies are planning versions of Zantac that should be excluded because they would violate the second patent.

113.   The company argues that what the dealers are calling new competition has been in place for years.

114.   The company argues the changes will help make Norilsk more efficient and reduce its tax liabilities.

115.   The company argues, however, that the vaccine worked in a subset of patients with stronger immune systems, and it will present data on this in Argentina.

116.   The competing companies have argued successfully to date that their stents are significantly different in design.

117.   The companies also argue that increased competition will bring down rates, although to what extent is highly debatable.

118.   The companies argue that current prices are justified by the billions of dollars they spend on research.

119.   The companies argue that expansion through mergers and acquisitions is cheaper than investing in new licenses and network expansion.

120.   The companies argued, however, that the deal would allow them to cut costs and thus prices.